Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Puma's Neratinib SUMMIT Study Shows Potential & Pitfalls Of Precision Medicine

Executive Summary

"Basket trial" design allowed Puma to identify certain cohorts for further study, but also missed in areas where neratinib was expected to work.

You may also be interested in...



US FDA Seeks Ways To Prevent Non-Responders From Sinking Tissue-Agnostic Indications

Agency officials and oncologists debate considerations where a data package overwhelms non-responders in favor of a tissue-agnostic indication.

Loxo '292 And Cancer Drug Development Today: So Much Promise, So Many Questions

Loxo data on the RET inhibitor LOXO-292 impressed at ASCO, so much so the company is looking to talk to regulators about the results after only a single-arm Phase I trial – but it's not a silver bullet as a tissue-agnostic treatment. Data on a separate target, PI3K, underwhelmed in breast cancer. Tissue of origin remains important, though the reasons why are not entirely understood. 

US FDA Outlines Streamlined Development Path For Targeted Therapies

But reminds sponsors that more trials could be ordered post-approval, which may be important in face of evidence that tissue-agnostic cancer therapies are not always equally effective.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS120361

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel